Results 191 to 200 of about 626,377 (227)

Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in familial hypercholesterolemia subjects. [PDF]

J Transl Med
Bosco G, Di Giacomo Barbagallo F, Di Marco M, Scilletta S, Miano N, Pistritto C, Tiralongo M, Di Stefano C, Pennisi G, De Francesco EM, Malaguarnera R, Di Pino A, Piro S, Scicali R.   +13 more
europepmc   +1 more source

PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre observational study. [PDF]

Sci Rep
Akhtar W, Khan T, Neves E, Browne C, Tawil M, Lyster H, Dar O.   +6 more
europepmc   +1 more source

Oral PCSK9 Inhibitors

Current Atherosclerosis Reports
Purpose of review: In this review, we will discuss the data from early clinical studies of MK-0616 and summarize clinical trials of other oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
Christie M. Ballantyne
exaly   +5 more sources

PCSK9 inhibitors for treating hypercholesterolemia

Expert Opinion on Pharmacotherapy, 2020
Introduction: Scientific evidence on subjects treated with statin or other lipid-lowering treatments has established that treatments aiming to lower low-density lipoprotein cholesterol (LDL-C) can reduce atherosclerosis.
Livia Pisciotta, Anna Laura Cremonini, Italo Porto   +2 more
exaly   +4 more sources

Safety of PCSK9 inhibitors

Biomedicine and Pharmacotherapy, 2022
annually in Europe, 4 million people die from cardiovascular diseases, the main cause of which is atherosclerosis. In order to slow down the development of atherosclerotic plaques, the main therapeutic goal is to lower LDL cholesterol (LDL-C) level. Undoubtedly, statins are the basis of lipid-lowering therapy for many years.
Grzegorz Grześk, Anna Wołowiec, Joanna Osiak   +2 more
exaly   +3 more sources

PCSK9 Inhibitors: From Nature’s Lessons to Clinical Utility

Endocrine, Metabolic and Immune Disorders - Drug Targets, 2020
Background: Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors are a novel class of non-statin lipid lowering therapy that reduce LDL-cholesterol by 50 - 6044,.
Alet Van Tonder, Naresh Ranjith, Virendra Rambiritch   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

PCSK9 inhibitors

Current Opinion in Lipidology, 2013
To summarize the therapeutic strategies to inhibit PCSK9 and to describe the main results obtained in phase I and II trials with monoclonal antibodies targeting PCSK9.Among the various approaches for PCSK9 inhibition, human data are only available for inhibition of PCSK9 binding to LDL receptor by monoclonal antibodies.
openaire   +2 more sources

PCSK9 inhibitors and cardiovascular outcomes

Expert Opinion on Biological Therapy, 2019
Introduction: Dyslipidemia, particularly elevated low-density lipoprotein cholesterol (LDL-C), is a key risk factor for atherosclerotic cardiovascular disease (ASCVD), and lipid-lowering drugs are beneficial for the primary and secondary prevention of cardiovascular (CV) disease.
Daniel, Steffens, Peter, Bramlage, Céline, Scheeff, Mario, Kasner, Adel, Hassanein, Julian, Friebel, Ursula, Rauch-Kröhnert   +6 more
openaire   +2 more sources

Lipid lowering with PCSK9 inhibitors

Nature Reviews Cardiology, 2014
Statins are the most-effective therapy currently available for lowering the LDL-cholesterol (LDL-C) level and preventing cardiovascular events. Additional therapies are necessary for patients who cannot reach the target LDL-C level when taking the maximum-tolerated dose of a statin.
Razvan T, Dadu, Christie M, Ballantyne
openaire   +2 more sources